Literature DB >> 8190701

Characterization of the CGRP receptor and mechanisms of action in rat mesenteric small arteries.

S Lei1, M J Mulvany, N C Nyborg.   

Abstract

Rat alpha-calcitonin gene-related peptide-induced concentration-dependent (100 pM-10 nM) relaxations in rat mesenteric small arteries (i.d. approximately 220 microns) contracted with noradrenaline, prostaglandin F2 alpha or K+, however, the maximal relaxation depended on the precontractile stimulus, being highest (95%) in arteries contracted with PGF2 alpha and lowest (51%) in arteries contracted with 125 mM K+. The relaxation was inhibited between 10 pM and 1 nM by removal of the endothelium, but was not antagonized by glibenclamide (1 microM), tetraethylammonium (30 mM), apamine (0.3 microM) and 4-aminopyridine (3 mM). The concentration-response curve to rat alpha-CGRP and human beta-CGRP was shifted to the right in the presence of 1 microM human alpha-CGRP(8-37) indicating a receptor affinity, -log(KB[M]), equal to 7.2 and 7.0, respectively. It is concluded that the relaxation induced by CGRP depends minimally on the endothelium and K(+)-channel opening is not a principal process in the relaxing effect of CGRP, thus a third mechanism must mediate the relaxation in these vessels. The main CGRP receptor type mediating relaxation in rat mesenteric small arteries belongs to the CGRP1 subtype.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8190701     DOI: 10.1111/j.1600-0773.1994.tb01087.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  9 in total

1.  Receptors mediating CGRP-induced relaxation in the rat isolated thoracic aorta and porcine isolated coronary artery differentiated by h(alpha) CGRP(8-37).

Authors:  F M Wisskirchen; D W Gray; I Marshall
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

2.  Pathway-specific effects of calcitonin gene-related peptide on irideal arterioles of the rat.

Authors:  C E Hill; D J Gould
Journal:  J Physiol       Date:  1997-12-15       Impact factor: 5.182

3.  Electrophysiological effects of activating the peptidergic primary afferent innervation of rat mesenteric arteries.

Authors:  W R Dunn; T A Hardy; J A Brock
Journal:  Br J Pharmacol       Date:  2003-08-04       Impact factor: 8.739

4.  Acetaminophen (Paracetamol) Metabolites Induce Vasodilation and Hypotension by Activating Kv7 Potassium Channels Directly and Indirectly.

Authors:  Jennifer van der Horst; Rian W Manville; Katie Hayes; Morten B Thomsen; Geoffrey W Abbott; Thomas A Jepps
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-03-19       Impact factor: 8.311

5.  Endothelial nitric oxide modulates perivascular sensory neurotransmission in the rat isolated mesenteric arterial bed.

Authors:  Vera Ralevic
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

6.  D. russelii Venom Mediates Vasodilatation of Resistance Like Arteries via Activation of Kv and KCa Channels.

Authors:  Rahini Kakumanu; Sanjaya Kuruppu; Lachlan D Rash; Geoffrey K Isbister; Wayne C Hodgson; Barbara K Kemp-Harper
Journal:  Toxins (Basel)       Date:  2019-04-01       Impact factor: 4.546

7.  Vampire Venom: Vasodilatory Mechanisms of Vampire Bat (Desmodus rotundus) Blood Feeding.

Authors:  Rahini Kakumanu; Wayne C Hodgson; Ravina Ravi; Alejandro Alagon; Richard J Harris; Andreas Brust; Paul F Alewood; Barbara K Kemp-Harper; Bryan G Fry
Journal:  Toxins (Basel)       Date:  2019-01-08       Impact factor: 4.546

8.  Zinc drives vasorelaxation by acting in sensory nerves, endothelium and smooth muscle.

Authors:  Ashenafi H Betrie; James A Brock; Osama F Harraz; Ashley I Bush; Guo-Wei He; Mark T Nelson; James A Angus; Christine E Wright; Scott Ayton
Journal:  Nat Commun       Date:  2021-06-01       Impact factor: 14.919

9.  Endosomal proteolysis regulates calcitonin gene-related peptide responses in mesenteric arteries.

Authors:  A J McNeish; B T Roux; S-B Aylett; A M Van Den Brink; G S Cottrell
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.